Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention


  Free Subscription

Articles published in Hepatology

Retrieve available abstracts of 171 articles:
HTML format

Single Articles

    October 2022
  1. BALOG S, Fujiwara R, Pan SQ, El-Baradie KB, et al
    Emergence of highly profibrotic and proinflammatory Lrat(+) Fbln2(+) hepatic stellate cell subpopulation in alcoholic hepatitis.
    Hepatology. 2022 Oct 1. doi: 10.1002/hep.32793.
    PubMed     Abstract available

    September 2022
  2. YIP TC, Wong VW, Wong GL
    Does hepatic steatosis impact chronic hepatitis B?
    Hepatology. 2022 Sep 24. doi: 10.1002/hep.32803.

  3. MAK LY, Hui RW, Lee CH, Mao X, et al
    Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
    Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
    PubMed     Abstract available

  4. JACHS M, Tillmann HL
    Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
    Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.

  5. YING D, He Q, Tian W, Chen Y, et al
    Urine Is a Viral Antigen Reservoir in Hepatitis E Virus Infection.
    Hepatology. 2022 Sep 15. doi: 10.1002/hep.32745.
    PubMed     Abstract available

  6. ALZUA GP, Pihl AF, Offersgaard A, Velazquez-Moctezuma R, et al
    Identification of novel neutralizing determinants for protection against hepatitis C virus.
    Hepatology. 2022 Sep 3. doi: 10.1002/hep.32772.
    PubMed     Abstract available

  7. PAL S, Dey D, Chakraborty BC, Nandi M, et al
    Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV-specific T-cell response and homing.
    Hepatology. 2022;76:759-774.
    PubMed     Abstract available

    August 2022
  8. LOUREIRO D, Tout I, Narguet S, Bed CM, et al
    Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C or nonalcoholic steatohepatitis.
    Hepatology. 2022 Aug 16. doi: 10.1002/hep.32731.
    PubMed     Abstract available

  9. WU Y, Hao X, Wei H, Sun R, et al
    TIGIT blockade elicits potent anti-tumor immunity in naturally occurring hepatitis B virus-related hepatocellular carcinoma in mice.
    Hepatology. 2022 Aug 8. doi: 10.1002/hep.32715.
    PubMed     Abstract available

    July 2022
  10. TRUDEAU S, Mendiratta V, Dababneh Y, Hollingsworth J, et al
    Letter to the Editor: Successful treatment of multidrug resistant hepatitis C after >12 months of continuous therapy with direct-acting antivirals.
    Hepatology. 2022 Jul 27. doi: 10.1002/hep.32688.

  11. SHEHRYAR M, Asif MZ, Umair M
    Letter to the Editor: County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017.
    Hepatology. 2022 Jul 26. doi: 10.1002/hep.32685.

  12. NASSAL M
    How many steps to a feasible mouse model of hepatitis B virus infection?
    Hepatology. 2022 Jul 24. doi: 10.1002/hep.32684.

  13. ELSHEIKH R, Tien HT, Makram AM, Van NT, et al
    Acute Hepatitis of Unknown Origin in Children: Behind the Statistics.
    Hepatology. 2022 Jul 21. doi: 10.1002/hep.32682.
    PubMed     Abstract available

  14. PAPATHEODORIDI M, Lok AS, Papatheodoridis GV
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma - Authors' reply.
    Hepatology. 2022 Jul 20. doi: 10.1002/hep.32673.

  15. JIN ZC, Chen JJ, Luo B, Zhang WH, et al
    Letter to the Editor: Hepatitis B virus reactivation in immune checkpoint inhibitor-based combination therapies for hepatocellular carcinoma.
    Hepatology. 2022 Jul 15. doi: 10.1002/hep.32672.

  16. BITTERMANN T, Lewis JD, Levy C, Goldberg DS, et al
    Sociodemographic and geographic differences in the U.S. epidemiology of autoimmune hepatitis with and without cirrhosis.
    Hepatology. 2022 Jul 10. doi: 10.1002/hep.32653.
    PubMed     Abstract available

  17. FUNG S, Choi HSJ, Gehring A, Janssen HLA, et al
    Getting to HBV cure: The promising paths forward.
    Hepatology. 2022;76:233-250.
    PubMed     Abstract available

  18. WU CR, Kim HJ, Sun CP, Chung CY, et al
    Mapping the conformational epitope of a therapeutic monoclonal antibody against HBsAg by in vivo selection of HBV escape variants.
    Hepatology. 2022;76:207-219.
    PubMed     Abstract available

  19. SINGH SP, Mishra AK, Jindal A
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcoholic hepatitis - more questions than answers !
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32648.

  20. GUPTA S, Nath P, Anand AC
    Letter to the Editor: Combination treatment with IL- 1 antagonist, pentoxifylline & zinc for severe alcoholic hepatitis: Are we there yet?
    Hepatology. 2022 Jul 1. doi: 10.1002/hep.32646.

    June 2022
  21. BARNES E, Cooke GS, Lauer G, Chung RT, et al
    Implementation of a Controlled Human Infection Model for Evaluation of HCV Vaccine Candidates.
    Hepatology. 2022 Jun 23. doi: 10.1002/hep.32632.
    PubMed     Abstract available

  22. ZHAO K, Guo F, Wang J, Zhong Y, et al
    Limited disassembly of cytoplasmic hepatitis B virus nucleocapsids restricts viral infection in murine hepatic cells.
    Hepatology. 2022 Jun 19. doi: 10.1002/hep.32622.
    PubMed     Abstract available

  23. XU C, Fan J, Liu D, Tuerdi A, et al
    Alpha-kinase 1 (ALPK1) Agonist, DF-006 Demonstrates Potent Efficacy in Murine and Primary Human Hepatocyte Models of Hepatitis B.
    Hepatology. 2022 Jun 14. doi: 10.1002/hep.32614.
    PubMed     Abstract available

  24. MA X, Chen A, Melo L, Clemente-Sanchez A, et al
    Loss of hepatic DRP1 exacerbates alcoholic hepatitis by inducing megamitochondria and mitochondrial maladaptation.
    Hepatology. 2022 Jun 13. doi: 10.1002/hep.32604.
    PubMed     Abstract available

  25. AHMAD A
    Letter to the Editor: Recovery and outcomes of patients denied early liver transplantation for severe alcohol-associated hepatitis.
    Hepatology. 2022 Jun 11. doi: 10.1002/hep.32607.
    PubMed     Abstract available

  26. AHMAD A, Chaudhry HUR
    Letter to the Editor: Outcomes of pregnancy in autoimmune hepatitis: A population-based study.
    Hepatology. 2022 Jun 10. doi: 10.1002/hep.32600.

  27. WANG CY, Deng Y, Li P, Zheng S, et al
    Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
    Hepatology. 2022;75:1373-1385.
    PubMed     Abstract available

    May 2022
  28. HARRINGTON C, Krishnan S, Mack CL, Cravedi P, et al
    Non-Invasive Biomarkers for the Diagnosis and Management of Autoimmune Hepatitis.
    Hepatology. 2022 May 25. doi: 10.1002/hep.32591.
    PubMed     Abstract available

  29. CHUNG Y, Heneghan MA
    Reply to: Medical therapy of autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 19. doi: 10.1002/hep.32579.

  30. EFE C, Purnak T
    Medical therapy of Autoimmune hepatitis in pregnancy.
    Hepatology. 2022 May 18. doi: 10.1002/hep.32576.

  31. EFE C, Kulkarni AV, Beretta-Piccoli BT, Magro B, et al
    Liver injury after SARS-CoV-2 vaccination: Features of immune-mediated hepatitis, role of corticosteroid therapy and outcome.
    Hepatology. 2022 May 14. doi: 10.1002/hep.32572.
    PubMed     Abstract available

    Another important step towards a prophylactic vaccine against hepatitis C.
    Hepatology. 2022 May 3. doi: 10.1002/hep.32557.

  33. MULCAHY VL, Mells GF
    Commentary on Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 May 2. doi: 10.1002/hep.32547.

  34. PAPATHEODORIDI M, Tampaki M, Lok AS, Papatheodoridis GV, et al
    Risk of HBV reactivation during therapies for HCC: A systematic review.
    Hepatology. 2022;75:1257-1274.
    PubMed     Abstract available

    April 2022
  35. KUMAR A, Rajani D, Kumar S
    Letter to the editor: HBV genotype: a significant risk factor in determining which patients with chronic HBV infection should undergo surveillance for HCC: The hepatitis B Alaska study.
    Hepatology. 2022 Apr 28. doi: 10.1002/hep.32544.

  36. WOLFISBERG R, Thorselius CE, Salinas E, Elrod E, et al
    Neutralization and receptor usage of infectious culture derived rat hepacivirus as a model for hepatitis C.
    Hepatology. 2022 Apr 21. doi: 10.1002/hep.32535.
    PubMed     Abstract available

  37. LUCEY MR, Thursz M
    We need a new approach to clinical trials in alcohol-associated hepatitis. Is there a lesson in RECOVERY?
    Hepatology. 2022 Apr 13. doi: 10.1002/hep.32523.

    The remarkable success of the vaccine for a killer virus: Hepatitis B.
    Hepatology. 2022 Apr 11. doi: 10.1002/hep.32346.

  39. DEFFIEU MS, Clement CMH, Dorobantu CM, Partiot E, et al
    Occludin stalls HCV particle dynamics apart from hepatocyte tight junctions, promoting virion internalization.
    Hepatology. 2022 Apr 7. doi: 10.1002/hep.32514.
    PubMed     Abstract available

  40. WAT C, Gane E, Yuen MF, Pavlovic V, et al
    Hepatology. 2022;75:1050-1051.

    March 2022
  41. SUNDARAM V, Jalan R
    Letter to the editor: the role of acute-on-chronic liver failure in predicting recovery in severe alcoholic hepatitis.
    Hepatology. 2022 Mar 31. doi: 10.1002/hep.32495.

  42. DENG R, Liu S, Shen S, Guo H, et al
    Circulating hepatitis B virus RNA: From biology to clinical applications.
    Hepatology. 2022 Mar 28. doi: 10.1002/hep.32479.
    PubMed     Abstract available

  43. SZABO G, Mitchell M, McClain CJ, Dasarathy S, et al
    IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis.
    Hepatology. 2022 Mar 27. doi: 10.1002/hep.32478.
    PubMed     Abstract available

  44. BRUCE MG, Bruden D, Hurlburt D, Morris J, et al
    Protection and Antibody Levels 35 Years after Primary Series with Hepatitis B Vaccine and Response to a Booster Dose.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32474.
    PubMed     Abstract available

  45. LOUKACHOV V, van Dort K, Erken R, Reesink HW, et al
    Reponse to: Letter to the Editor concerning Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Mar 23. doi: 10.1002/hep.32472.

  46. DONNISON T, McGregor J, Chinnakannan S, Hutchings C, et al
    A pan-genotype hepatitis C virus viral vector vaccine generates T-cells and neutralizing antibodies in mice.
    Hepatology. 2022 Mar 21. doi: 10.1002/hep.32470.
    PubMed     Abstract available

  47. HE Q, Zhang F, Shu J, Li S, et al
    Immunocompromised rabbit model of chronic hepatitis E reveals liver fibrosis and distinct efficacy of different vaccination strategies.
    Hepatology. 2022 Mar 12. doi: 10.1002/hep.32455.
    PubMed     Abstract available

  48. HOWELL J, Hellard M
    Making child's play of tolerance: Defining the immune-viral interplay during combination entecavir and pegylated interferon therapy for immune tolerant hepatitis B infection.
    Hepatology. 2022 Mar 9. doi: 10.1002/hep.32450.

  49. GAVRISHEVA S, Abdurakhmanov D, Milovanova S, Nikulkina E, et al
    Letter to the Editor: High rate of clinical and immunological response in patients with HCV-associated cryoglobulinemia.
    Hepatology. 2022 Mar 8. doi: 10.1002/hep.32425.

    February 2022
  50. PATWA AK, Rungta S, Kumar V
    Nanoparticle therapeutic vaccine for hepatitis B: an unfulfilled dream.
    Hepatology. 2022 Feb 28. doi: 10.1002/hep.32421.

  51. D'AMBROSIO R, Lampertico P
    Is it time to refine HCC surveillance strategies in HCV cured patients?
    Hepatology. 2022 Feb 26. doi: 10.1002/hep.32430.

  52. ZHANG J, Zhao T, Wei L, Wu Y, et al
    Reply: epsilonPA-44 may expand the arsenal for chronic hepatitis B combination treatment towards functional cure.
    Hepatology. 2022 Feb 24. doi: 10.1002/hep.32423.

  53. PERRILLO RP, Lin HS, Schwarz KB, Rosenthal P, et al
    Changes in serum hepatitis B surface and e antigen, IP-10, and aminotransferase levels during combination therapy of immune tolerant chronic hepatitis B.
    Hepatology. 2022 Feb 21. doi: 10.1002/hep.32400.
    PubMed     Abstract available

  54. LI Y, Sun Y, Liu Y, Wang B, et al
    Genome-wide Meta-analysis Identifies Novel Susceptibility Loci for Autoimmune Hepatitis Type 1.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32417.
    PubMed     Abstract available

  55. CHUNG YY, Heneghan MA
    Autoimmune hepatitis in pregnancy: pearls and pitfalls.
    Hepatology. 2022 Feb 19. doi: 10.1002/hep.32410.
    PubMed     Abstract available

  56. INDOLFI G, Kelly D, Nebbia G, Iorio R, et al
    Sofosbuvir-Velpatasvir-Voxilaprevir in Adolescents 12 to 17 Years Old With Hepatitis C Virus Infection.
    Hepatology. 2022 Feb 3. doi: 10.1002/hep.32393.
    PubMed     Abstract available

  57. TU T, Zhang H
    Viral integrations in chronic Hepatitis B infection: purposeless passenger or problematic promoter of persistence?
    Hepatology. 2022 Feb 2. doi: 10.1002/hep.32388.

  58. YANG Y, Choi J, Chen Y, Invernizzi P, et al
    E. coli and the etiology of human PBC: Antimitochondrial antibodies and spreading determinants.
    Hepatology. 2022;75:266-279.
    PubMed     Abstract available

  59. WANG X, Wei Z, Cheng B, Li J, et al
    Endoplasmic reticulum stress promotes HBV production by enhancing use of the autophagosome/multivesicular body axis.
    Hepatology. 2022;75:438-454.
    PubMed     Abstract available

    January 2022
  60. HUANG V, Lewin C, Novy P
    Leveraging universal adult vaccination as part of a multipronged approach to eliminate hepatitis B in the US.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32376.

  61. JANG H, Lee YB, Moon H, Chung JW, et al
    Aspirin Use and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B With or Without Cirrhosis.
    Hepatology. 2022 Jan 31. doi: 10.1002/hep.32380.
    PubMed     Abstract available

  62. PAN CQ, Jacobson IM, Martin P, Kwo P, et al
    Letter to the editor: Both universal screening and vaccination are essential components of a multipronged approach to hepatitis B elimination.
    Hepatology. 2022 Jan 28. doi: 10.1002/hep.32366.

  63. ERKEN R, Loukachov V, van Dort K, van den Hurk A, et al
    Quantified integrated hepatitis B virus is related to viral activity in chronic hepatitis B patients.
    Hepatology. 2022 Jan 24. doi: 10.1002/hep.32352.
    PubMed     Abstract available

  64. HUANG CH, Fan JH, Jeng WJ, Chang ST, et al
    Innate-like bystander-activated CD38(+) HLA-DR(+) CD8(+) T cells play a pathogenic role in patients with chronic hepatitis C.
    Hepatology. 2022 Jan 21. doi: 10.1002/hep.32349.
    PubMed     Abstract available

  65. PARK H, Lo-Ciganic WH, Huang J, Wu Y, et al
    Machine Learning Algorithms for Predicting Direct-Acting Antiviral Treatment Failure in Chronic Hepatitis C: An HCV-TARGET Analysis.
    Hepatology. 2022 Jan 16. doi: 10.1002/hep.32347.
    PubMed     Abstract available

  66. LOCKART I, Yeo MGH, Hajarizadeh B, Dore GJ, et al
    Hepatocellular carcinoma incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: a meta-analysis.
    Hepatology. 2022 Jan 14. doi: 10.1002/hep.32341.
    PubMed     Abstract available

  67. PAN JJ, Razumilava N
    Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: is less more?
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32330.

  68. SANDMANN L, Cornberg M
    Hepatocellular carcinoma and hepatitis B virus reactivation - a preventable condition not to be missed.
    Hepatology. 2022 Jan 10. doi: 10.1002/hep.32333.

  69. JINDAL A
    Oral antivirals in treatment naive chronic hepatitis C infection.
    Hepatology. 2022 Jan 5. doi: 10.1002/hep.32311.

  70. GINES P, Castera L, Lammert F, Graupera I, et al
    Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases.
    Hepatology. 2022;75:219-228.
    PubMed     Abstract available

    December 2021
  71. COHEN C, Moraras K, Jackson M, Kamischke M, et al
    Letter to the Editor: Importance of Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32304.

  72. CHEN VL, Ramrakhiani NS, Nguyen MH
    Hepatitis B screening-Universal or simplified semi-targeted but not the status quo.
    Hepatology. 2021 Dec 24. doi: 10.1002/hep.32303.

  73. KONDILI LA, Monti M, Quaranta MG, Gragnani L, et al
    A prospective study of DAA Effectiveness and Relapse Risk in HCV Cryoglobulinemic Vasculitis by the Italian PITER Cohort.
    Hepatology. 2021 Dec 16. doi: 10.1002/hep.32281.
    PubMed     Abstract available

  74. SUZUKI Y, Kakisaka K, Takikawa Y
    Letter to the Editor: Autoimmune hepatitis after COVID-19 vaccination: Need for population based-epidemiological study.
    Hepatology. 2021 Dec 13. doi: 10.1002/hep.32280.

  75. MUSTO J, Lucey MR, Rice J
    Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32275.

  76. JINDAL A
    Letter to the editor: Spontaneous recovery in patients denied early liver transplantation for severe alcoholic hepatitis-Need a closer look!
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32276.

  77. WEI L, Ploss A
    Rise above the stress-Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles.
    Hepatology. 2021 Dec 10. doi: 10.1002/hep.32273.

  78. LIBRERO JIMENEZ M, Lopez Garrido MA, Fernandez Cano MC
    Letter to the editor: Reactivation of HBV triggered by SARS-CoV-2 in a patient with cirrhosis.
    Hepatology. 2021 Dec 8. doi: 10.1002/hep.32271.

  79. CAO Z, Gui H, Sheng Z, Xin H, et al
    Letter to the editor: Exacerbation of autoimmune hepatitis after COVID-19 vaccination.
    Hepatology. 2021 Dec 4. doi: 10.1002/hep.32269.
    PubMed     Abstract available

  80. YURDAYDIN C, Keskin O, Yurdcu E, Caliskan A, et al
    A Phase ii dose finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis.
    Hepatology. 2021 Dec 3. doi: 10.1002/hep.32259.
    PubMed     Abstract available

  81. MURAYAMA A, Ozaki A, Saito H, Sawano T, et al
    Are Clinical Practice Guideline for Hepatitis C by the American Association for the Study of Liver Disease and Infectious Diseases Society of America Evidence-based? Financial Conflicts of Interest and Assessment of Quality of Evidence and Strength of
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32262.
    PubMed     Abstract available

  82. HE WQ, Guo GN, Li C
    The impact of hepatitis B vaccination in United States, 1999-2018.
    Hepatology. 2021 Dec 2. doi: 10.1002/hep.32265.
    PubMed     Abstract available

  83. WYATT B, Perumalswami PV, Mageras A, Miller M, et al
    A Digital Case-Finding Algorithm for Diagnosed but Untreated Hepatitis C: A Tool for Increasing Linkage to Treatment and Cure.
    Hepatology. 2021;74:2974-2987.
    PubMed     Abstract available

  84. ISNARD P, Larue M, Pitsch A, Duong Van Huyen JP, et al
    A Simple Bacterium Links Heart Infection to Inflammatory Liver Disease.
    Hepatology. 2021;74:3549-3551.

    November 2021
  85. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
    'Letter to the editor: Response to letter concerning our patient with post-vaccination autoimmune hepatitis like syndrome'.
    Hepatology. 2021 Nov 19. doi: 10.1002/hep.32248.
    PubMed     Abstract available

    Lettter to the editor on "Autoimmune hepatitis after COVID-19 vaccination".
    Hepatology. 2021 Nov 19. doi: 10.1002/hep.32249.
    PubMed     Abstract available

  87. WANG Y, Li Y, Zai W, Hu K, et al
    Hepatitis B Virus cccDNA Minichromosomes in Distinct Epigenetic Transcriptional States Differ in Their Vulnerability to Damage.
    Hepatology. 2021 Nov 15. doi: 10.1002/hep.32245.
    PubMed     Abstract available

  88. POLITI J, Guerras JM, Donat M, Belza MJ, et al
    Favorable impact in Hepatitis C related mortality following free-access to direct-acting antivirals in Spain.
    Hepatology. 2021 Nov 12. doi: 10.1002/hep.32237.
    PubMed     Abstract available

  89. TABERNERO D, Cortese MF, Rando-Segura A, Buti M, et al
    Letter to the Editor: standardization of HBV RNA assay for the different phases of chronic hepatitis B is essential.
    Hepatology. 2021 Nov 10. doi: 10.1002/hep.32227.
    PubMed     Abstract available

  90. TERRAULT NA, Wahed AS, Feld JJ, Cooper SL, et al
    Incidence and Prediction of HBsAg Seroconversion in a Prospective Multi-ethnic HBeAg-Negative Chronic Hepatitis B Cohort.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32231.
    PubMed     Abstract available

  91. KUIPERY A, Sanchez Vasquez JD, Mehrotra A, Feld JJ, et al
    Immunomodulation and RNA interference alter Hepatitis B Virus-specific CD8 T cell recognition of infected HepG2-NTCP.
    Hepatology. 2021 Nov 7. doi: 10.1002/hep.32230.
    PubMed     Abstract available

  92. ROY A, Dhiman RK
    Letter to the Editor: Recurrent Cryoglobulinemic Vasculitis in the Era of Direct-Acting Antivirals: A Story Beyond Sustained Virological Response 12.
    Hepatology. 2021;74:2909.

  93. GHANY MG, King WC, Lisker-Melman M, Lok ASF, et al
    Comparison of HBV RNA and Hepatitis B Core Related Antigen With Conventional HBV Markers Among Untreated Adults With Chronic Hepatitis B in North America.
    Hepatology. 2021;74:2395-2409.
    PubMed     Abstract available

  94. SHEN Y, Cingolani F, Malik SA, Wen J, et al
    Sex-Specific Regulation of Interferon-gamma Cytotoxicity in Mouse Liver by Autophagy.
    Hepatology. 2021;74:2745-2758.
    PubMed     Abstract available

  95. LEE BT, Tana MM, Kahn JA, Dara L, et al
    We Are Not Immune: Racial and Ethnic Disparities in Autoimmune Liver Diseases.
    Hepatology. 2021;74:2876-2887.
    PubMed     Abstract available

  96. OTERO SANCHEZ L, Karakike E, Njimi H, Putignano A, et al
    Clinical Course and Risk Factors for Infection in Severe Forms of Alcohol-Associated Liver Disease.
    Hepatology. 2021;74:2714-2724.
    PubMed     Abstract available

    October 2021
  97. BEKKI Y, Fenig Y
    Outcomes of Severe Alcohol-Related Hepatitis with or without Early Liver Transplantation.
    Hepatology. 2021 Oct 30. doi: 10.1002/hep.32219.
    PubMed     Abstract available

  98. LI M, Wong D, Vogel AS, Sack JS, et al
    Effect of corticosteroid dosing on outcomes in high-grade immune checkpoint inhibitor hepatitis.
    Hepatology. 2021 Oct 28. doi: 10.1002/hep.32215.
    PubMed     Abstract available

  99. KHANAM A, Kottilil S, Tang LSY
    PD-1 Expressing CD8+CXCR5+ Follicular T Cells Constitute Effector Rather Than Exhaustive Phenotype in Patients with Chronic Hepatitis B.
    Hepatology. 2021 Oct 24. doi: 10.1002/hep.32210.
    PubMed     Abstract available

  100. LAI CW, Nishio A, Hasan S, Kefalakes H, et al
    Spontaneous Clearance of Drug-Resistant Chronic Hepatitis C Virus Infection.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32205.
    PubMed     Abstract available

  101. HU K, Camila Perez-Matos M, Argemi J, Vilar E, et al
    Lipoprotein Z, A novel hepatotoxic lipoprotein, predicts outcome in alcoholic hepatitis.
    Hepatology. 2021 Oct 18. doi: 10.1002/hep.32203.
    PubMed     Abstract available

  102. LAWITZ EJ, Shevell DE, Tirucherai GS, Du S, et al
    BMS-986263 in Patients with Advanced Hepatic Fibrosis: 36-Week Results from a Randomized, Placebo-Controlled Phase 2 Trial.
    Hepatology. 2021 Oct 4. doi: 10.1002/hep.32181.
    PubMed     Abstract available

  103. KUSHNER T, Chappell CA
    Letter to the Editor: Pregnant Women and their Providers Want Direct-Acting Antivirals, and We Are Missing the Mark.
    Hepatology. 2021;74:2311-2312.

  104. MA Y, Su H, Yuksel M, Longhi MS, et al
    Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.
    Hepatology. 2021;74:2032-2046.
    PubMed     Abstract available

    September 2021
  105. YASSEEN AS, Kwong JC, Feld JJ, Kustra R, et al
    The viral hepatitis B care cascade: A population-based comparison of immigrant groups.
    Hepatology. 2021 Sep 19. doi: 10.1002/hep.32162.
    PubMed     Abstract available

  106. PALLA P, Vergadis C, Sakellariou S, Androutsakos T, et al
    Letter to the editor: Autoimmune hepatitis after COVID-19 vaccination. A rare adverse effect?
    Hepatology. 2021 Sep 15. doi: 10.1002/hep.32156.
    PubMed     Abstract available

  107. HUANG R, Liu J, Wang J, Li J, et al
    Letter to the Editor: Is hepatitis B virus genotype strongly associated with hepatocellular carcinoma risk in patients with chronic hepatitis B?
    Hepatology. 2021 Sep 14. doi: 10.1002/hep.32155.
    PubMed     Abstract available

  108. RAMRAKHIANI NS, Chen VL, Le M, Yeo YH, et al
    Optimizing Hepatitis B Virus Screening in the United States Using a Simple Demographics-Based Model.
    Hepatology. 2021 Sep 8. doi: 10.1002/hep.32142.
    PubMed     Abstract available

  109. COLL M, Arino S, Martinez-Sanchez C, Garcia-Pras E, et al
    Ductular Reaction Promotes Intrahepatic Angiogenesis Via Slit2-Robo1 Signaling.
    Hepatology. 2021 Sep 7. doi: 10.1002/hep.32140.
    PubMed     Abstract available

  110. TAUBERT R, Engel B, Diestelhorst J, Hupa-Breier KL, et al
    Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis.
    Hepatology. 2021 Sep 2. doi: 10.1002/hep.32134.
    PubMed     Abstract available

  111. DING WB, Wang MC, Yu J, Huang G, et al
    HBV/Pregenomic RNA Increases the Stemness and Promotes the Development of HBV-Related HCC Through Reciprocal Regulation With Insulin-Like Growth Factor 2 mRNA-Binding Protein 3.
    Hepatology. 2021;74:1480-1495.
    PubMed     Abstract available

  112. STERLING RK, King WC, Khalili M, Chung RT, et al
    A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
    Hepatology. 2021;74:1174-1189.
    PubMed     Abstract available

  113. TOMLINSON JE, Wolfisberg R, Fahnoe U, Patel RS, et al
    Pathogenesis, MicroRNA-122 Gene-Regulation, and Protective Immune Responses After Acute Equine Hepacivirus Infection.
    Hepatology. 2021;74:1148-1163.
    PubMed     Abstract available

    August 2021
  114. WANG CW, Grab J, Tana MM, Irani RA, et al
    Outcomes of Pregnancy in Autoimmune Hepatitis: A Population-Based Study.
    Hepatology. 2021 Aug 28. doi: 10.1002/hep.32132.
    PubMed     Abstract available

  115. WEI L, Zhao T, Zhang J, Mao Q, et al
    Efficacy and Safety of a Nanoparticle Therapeutic Vaccine in Patients with Chronic Hepatitis B: A Randomized Clinical Trial.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32109.
    PubMed     Abstract available

  116. LI Y, Yu P, Kessler AL, Shu J, et al
    Hepatitis E virus infection activates NLRP3 inflammasome antagonizing interferon response but therapeutically targetable.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32114.
    PubMed     Abstract available

  117. YIP TC, Wong VW, Wong GL
    Reply to Letters to the Editor: Clinical outcomes in COVID-19 patients with current or past hepatitis B virus infection.
    Hepatology. 2021 Aug 15. doi: 10.1002/hep.32116.
    PubMed     Abstract available

  118. JINDAL A
    Outcomes in chronic hepatitis B infection and COVID-19 - Not always benign !
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32108.
    PubMed     Abstract available

  119. OECHSLIN N, Da Silva N, Szkolnicka D, Cantrelle FX, et al
    Hepatitis E Virus RNA-Dependent RNA Polymerase is Involved in RNA Replication and Infectious Particle Production.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32100.
    PubMed     Abstract available

  120. LV XH, Yang JL, Deng K
    Letter to the Editor: unanswered questions about hepatitis B virus infection in patients with COVID-19.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32098.
    PubMed     Abstract available

  121. MUSTO J, Stanfield D, Ley D, Lucey MR, et al
    Recovery and Outcomes of Patients Denied Early Liver Transplantation (LT) for Severe Alcohol-Related Hepatitis (AH).
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32110.
    PubMed     Abstract available

  122. HLADY RA, Zhao X, El Khoury LY, Luna A, et al
    Interferon drives hepatitis C virus scarring of the epigenome and creates targetable vulnerabilities following viral clearance.
    Hepatology. 2021 Aug 13. doi: 10.1002/hep.32111.
    PubMed     Abstract available

  123. TOYODA H, Leong J, Landis C, Atsukawa M, et al
    Treatment and Renal Outcomes Up to 96 Weeks After Tenofovir Alafenamide Switch From Tenofovir Disoproxil Fumarate in Routine Practice.
    Hepatology. 2021;74:656-666.
    PubMed     Abstract available

  124. LIANG YJ, Teng W, Chen CL, Sun CP, et al
    Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
    Hepatology. 2021;74:641-655.
    PubMed     Abstract available

    July 2021
  125. LOK AS, Negro F, Asselah T, Farci P, et al
    Endpoints and new options for treatment of chronic hepatitis D.
    Hepatology. 2021 Jul 31. doi: 10.1002/hep.32082.
    PubMed     Abstract available

  126. CHOLANKERIL G, Goli K, Rana A, Hernaez R, et al
    Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the United States.
    Hepatology. 2021 Jul 26. doi: 10.1002/hep.32067.
    PubMed     Abstract available

  127. MCMAHON BJ, Nolen S, Snowball M, Homan C, et al
    Hepatitis B Virus (HBV) Genotype: A Significant Risk Factor in Determining which Patients with Chronic HBV Infection should Undergo Surveillance for Hepatocellular Carcinoma: The Hepatitis B Alaska (HEP-B-AK) Study.
    Hepatology. 2021 Jul 22. doi: 10.1002/hep.32065.
    PubMed     Abstract available

  128. SULKOWSKI MS, Moon J, Sherman K, Morelli G, et al
    A Pragmatic, Randomized Controlled Trial of Oral Antivirals for the Treatment of Chronic Hepatitis C: THE PRIORITIZE STUDY.
    Hepatology. 2021 Jul 13. doi: 10.1002/hep.32053.
    PubMed     Abstract available

  129. KIM OK, Nam DE, Hahn YS
    The Panx1/P2X4 pathway controls the secretion of miRNA-containing exosomes by HCV-infected hepatocytes.
    Hepatology. 2021 Jul 4. doi: 10.1002/hep.32042.
    PubMed     Abstract available

  130. CHO Y, Szabo G
    Two Faces of Neutrophils in Liver Disease Development and Progression.
    Hepatology. 2021;74:503-512.
    PubMed     Abstract available

    June 2021
  131. NGUYEN LN, Nguyen LNT, Zhao J, Schank M, et al
    Immune activation induces telomeric DNA damage and promotes short-lived effector T cell differentiation in chronic HCV infection.
    Hepatology. 2021 Jun 10. doi: 10.1002/hep.32008.
    PubMed     Abstract available

  132. BEUDEKER BJB, Janssen HLA, Boonstra A
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response?
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32003.
    PubMed     Abstract available

  133. DE PASQUALE C, Campana S, Pollicino T, Ferlazzo G, et al
    Letter to the Editor: Entecavir treatment restores the anti-hepatitis B virus immune response? Author's Reply.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32004.
    PubMed     Abstract available

  134. LIM AG, Stone J, Hajarizadeh B, Byrne M, et al
    Evaluating the prevention benefit of HCV treatment: Modelling the SToP-C treatment as prevention study in prisons.
    Hepatology. 2021 Jun 9. doi: 10.1002/hep.32002.
    PubMed     Abstract available

  135. ROBERTS H, Ly KN, Yin S, Hughes E, et al
    Prevalence of Hepatitis B Virus (HBV) Infection, Vaccine-Induced Immunity, and Susceptibility among At-Risk Populations: U.S. Households, 2013-2018.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31991.
    PubMed     Abstract available

  136. YANG Z, Zhang T, Kusumanchi P, Tang Q, et al
    Transcriptomic analysis reveals the miRNAs responsible for liver regeneration associated with mortality in alcoholic hepatitis.
    Hepatology. 2021 Jun 7. doi: 10.1002/hep.31994.
    PubMed     Abstract available

  137. CHOI J, Yoo S, Lim YS
    Comparison of Long-Term Clinical Outcomes Between Spontaneous and Therapy-Induced HBsAg Seroclearance.
    Hepatology. 2021;73:2155-2166.
    PubMed     Abstract available

    May 2021
  138. GANE E, Yuen MF, Kim DJ, Chan HL, et al
    Clinical Study of Single Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients with Chronic Hepatitis B.
    Hepatology. 2021 May 26. doi: 10.1002/hep.31920.
    PubMed     Abstract available

  139. MESZAROS M, Truchi R, Ouzan D, Tran A, et al
    Sofosbuvir, glecaprevir, pibrentasvir, and ribavirin as a rescue therapy in difficult-to-treat hepatitis C patients.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31909.
    PubMed     Abstract available

  140. CLIPMAN SJ, Mehta SH, Rodgers MA, Duggal P, et al
    Spatiotemporal phylodynamics of hepatitis C among people who inject drugs in India.
    Hepatology. 2021 May 18. doi: 10.1002/hep.31912.
    PubMed     Abstract available

  141. RIEDL T, Faure-Dupuy S, Rolland M, Schuehle S, et al
    HIF1alpha-mediated RelB/APOBEC3B downregulation allows Hepatitis B Virus persistence.
    Hepatology. 2021 May 15. doi: 10.1002/hep.31902.
    PubMed     Abstract available

  142. YIP TC, Wong VW, Lui GC, Chow VC, et al
    Current and past infections of hepatitis B virus do not increase mortality in patients with COVID-19.
    Hepatology. 2021 May 7. doi: 10.1002/hep.31890.
    PubMed     Abstract available

  143. LIAO H, Wang J, Liu Y, Chen J, et al
    Letter to the Editor: Why Serum Hepatitis B Virus (HBV) DNA Has Higher Frequency of rtM204I/V Mutation Than Serum HBV RNA in the Same Individual?
    Hepatology. 2021;73:2075-2076.

  144. BRUNT EM, Kleiner DE, Carpenter DH, Rinella M, et al
    NAFLD: Reporting Histologic Findings in Clinical Practice.
    Hepatology. 2021;73:2028-2038.
    PubMed     Abstract available

    April 2021
  145. ISHIKAWA T, Sasaki R, Matsuda T, Saeki I, et al
    Successful Management with Dual Therapy of Lenvatinib and Macitentan for Hepatocellular Carcinoma with Portopulmonary Hypertension.
    Hepatology. 2021 Apr 26. doi: 10.1002/hep.31865.
    PubMed     Abstract available

  146. LIU Y, Wang S, Hu L
    Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B.
    Hepatology. 2021 Apr 8. doi: 10.1002/hep.31842.
    PubMed     Abstract available

  147. LEE YB, Lee J
    Letter to the Editor: Use of New Defined Metabolic Risk Factors in Patients with Chronic Hepatitis B - The Authors' reply.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31844.
    PubMed     Abstract available

  148. JONAS MM, Rhee S, Kelly DA, Del Valle-Segarra A, et al
    Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study.
    Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841.
    PubMed     Abstract available

  149. ABUTALEB A, Khatun M, Clement J, Baidya A, et al
    A Model of Care Optimized for Marginalized Remote Population Unravels Migration Pattern in India.
    Hepatology. 2021;73:1261-1274.
    PubMed     Abstract available

    February 2021
  150. YAMASHITA T, Koshikawa N, Shimakami T, Terashima T, et al
    Serum laminin gamma2 monomer as a novel diagnostic and predictive biomarker for hepatocellular carcinoma.
    Hepatology. 2021 Feb 20. doi: 10.1002/hep.31758.
    PubMed     Abstract available

  151. CHEMIN I, Pujol FH, Scholtes C, Loureiro CL, et al
    Preliminary Evidence for Hepatitis Delta Virus Exposure in Patients Who Are Apparently Not Infected With Hepatitis B Virus.
    Hepatology. 2021;73:861-864.

  152. KIM GW, Imam H, Khan M, Mir SA, et al
    HBV-Induced Increased N6 Methyladenosine Modification of PTEN RNA Affects Innate Immunity and Contributes to HCC.
    Hepatology. 2021;73:533-547.
    PubMed     Abstract available

  153. CHEN J, Li Y, Lai F, Wang Y, et al
    Functional Comparison of Interferon-alpha Subtypes Reveals Potent Hepatitis B Virus Suppression by a Concerted Action of Interferon-alpha and Interferon-gamma Signaling.
    Hepatology. 2021;73:486-502.
    PubMed     Abstract available

  154. ZHAO X, Fan H, Chen X, Zhao X, et al
    Hepatitis B Virus DNA Polymerase Restrains Viral Replication Through the CREB1/HOXA Distal Transcript Antisense RNA Homeobox A13 Axis.
    Hepatology. 2021;73:503-519.
    PubMed     Abstract available

    November 2020
  155. HAFEZI M, Lin M, Chia A, Chua A, et al
    Immunosuppressive Drug Resistant Armored TCR T cells for immune-therapy of HCC in liver transplant patients.
    Hepatology. 2020 Nov 29. doi: 10.1002/hep.31662.
    PubMed     Abstract available

    ImmTAV, a New Immunotherapy Targeting the Source of HBV Infection.
    Hepatology. 2020;72:1514-1517.

    September 2020
  157. ZHAO Q, Guo JT
    Have the Starting Lineup of Five for Hepatitis B Virus Covalently Closed Circular DNA Synthesis Been Identified?
    Hepatology. 2020;72:1142-1144.

    August 2020
  158. KAPILA N, Rahman AU, Zervos XB
    Hepatology. 2020;72:788.

    July 2020
  159. THAN NN, Cataluna JG, Majumdar A
    Acute confusion post liver transplantation: HE or not HE, that is the question.
    Hepatology. 2020 Jul 6. doi: 10.1002/hep.31452.
    PubMed     Abstract available

    Is It Time to Consider Gut Microbiome Readouts for Precision Diagnosis and Treatment of Alcoholic Liver Disease?
    Hepatology. 2020;72:4-6.

    April 2020
  161. BEYLS C, Haustermans K, Deroose CM, Pans S, et al
    Could autoimmune disease contribute to the abscopal effect in metastatic hepatocellular carcinoma?
    Hepatology. 2020 Apr 29. doi: 10.1002/hep.31186.
    PubMed     Abstract available

  162. MCGLYNN KA, Petrick JL, El-Serag HB
    Epidemiology of Hepatocellular Carcinoma.
    Hepatology. 2020 Apr 22. doi: 10.1002/hep.31288.
    PubMed     Abstract available

  163. YANG Y, Zhao X, Wang Z, Shu W, et al
    Nuclear Sensor Interferon-Inducible Protein 16 Inhibits the Function of Hepatitis B Virus Covalently Closed Circular DNA by Integrating Innate Immune Activation and Epigenetic Suppression.
    Hepatology. 2020;71:1154-1169.
    PubMed     Abstract available

    March 2020
  164. SZE KM, Ho DW, Chiu YT, Tsui YM, et al
    HBV-TERT Promoter Integration Harnesses Host ELF4 Resulting in TERT Gene Transcription in Hepatocellular Carcinoma.
    Hepatology. 2020 Mar 14. doi: 10.1002/hep.31231.
    PubMed     Abstract available

  165. ZENG J, Wu D, Hu H, Young JAT, et al
    Activation of the liver X receptor pathway inhibits HBV replication in primary human hepatocytes.
    Hepatology. 2020 Mar 7. doi: 10.1002/hep.31217.
    PubMed     Abstract available

    December 2019
  166. STUART L, Lambourne B, Turner P, Jones DE, et al
    HEP-19-1549 Pembrolizumab as a cause of cholangiopathy in a patient with metastatic melanoma.
    Hepatology. 2019 Dec 23. doi: 10.1002/hep.31089.
    PubMed     Abstract available

    October 2019
  167. LIU F, Goh GB, Tiniakos D, Wee A, et al
    qFIBS: A Novel Automated Technique for Quantitative Evaluation of Fibrosis, Inflammation, Ballooning, and Steatosis in Patients With Nonalcoholic Steatohepatitis.
    Hepatology. 2019 Oct 10. doi: 10.1002/hep.30986.
    PubMed     Abstract available

    September 2019
  168. LEVITSKY J, Asrani SK, Klintmalm G, Schiano T, et al
    Discovery and validation of a biomarker model (preserve) predictive of renal outcomes after liver transplantation.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30939.
    PubMed     Abstract available

  169. DONG B, Zhou Y, Wang W, Scott J, et al
    Vitamin D receptor activation in liver macrophages ameliorates hepatic inflammation, steatosis, and insulin resistance in mice.
    Hepatology. 2019 Sep 11. doi: 10.1002/hep.30937.
    PubMed     Abstract available

    August 2019
  170. MATYAS C, Erdelyi K, Trojnar E, Zhao S, et al
    Interplay of liver-heart inflammatory axis and cannabinoid 2 receptor signalling in an experimental model of hepatic cardiomyopathy.
    Hepatology. 2019 Aug 30. doi: 10.1002/hep.30916.
    PubMed     Abstract available

  171. ZHOU Y, Dong B, Kim KH, Choi S, et al
    Vitamin D receptor activation in liver macrophages protects against hepatic endoplasmic reticulum stress in mice.
    Hepatology. 2019 Aug 5. doi: 10.1002/hep.30887.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.